Y-mAbs Therapeutics (NASDAQ:YMAB) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research report released on Monday, Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group reiterated a buy rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reissued a buy rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Truist Financial began coverage on Y-mAbs Therapeutics in a report on Friday, June 28th. They issued a buy rating and a $21.00 price objective for the company. BMO Capital Markets cut their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an outperform rating on the stock in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group raised Y-mAbs Therapeutics to a strong-buy rating in a research note on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of Moderate Buy and an average target price of $21.14.

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB opened at $13.37 on Monday. The firm’s fifty day moving average price is $12.50 and its two-hundred day moving average price is $13.63. The stock has a market cap of $586.72 million, a PE ratio of -27.29 and a beta of 0.70. Y-mAbs Therapeutics has a fifty-two week low of $4.69 and a fifty-two week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The firm had revenue of $22.80 million for the quarter, compared to the consensus estimate of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same quarter in the prior year, the firm earned ($0.14) EPS. As a group, sell-side analysts predict that Y-mAbs Therapeutics will post -0.57 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 21.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Large investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its position in shares of Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after purchasing an additional 67,233 shares in the last quarter. Squarepoint Ops LLC raised its stake in Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after buying an additional 74,452 shares during the period. XTX Topco Ltd bought a new position in Y-mAbs Therapeutics in the second quarter worth approximately $297,000. Dimensional Fund Advisors LP grew its stake in Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after acquiring an additional 65,732 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Y-mAbs Therapeutics by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after acquiring an additional 2,760 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.